Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 1;4:2. doi: 10.1038/s41525-019-0077-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Analysis of triple-evidenced genes and enriched pathways. a Genes supported by one, two or three evidences in LUSC. b The number of triple-evidenced genes shared between the 13 cancers. c The differential methylation and expression levels of the top five triple-evidenced genes (difference = normal value − tumor value) that are most common in the 13 cancers. X axis is the difference of methylation, y axis is the log2(RPKM ratio) to represent the gene expression difference. One red circle in each graph represents a cancer type. d The top five pathways enriched in the 13 cancers, the red dot indicates the cancer type in which a pathway is enriched